Epitope vaccine for prevention and reversion of AD pathology
(No. in US: WO002009029272A3. Date: 12/23/2009.)
Vaccines for treating Alzheimer’s disease (AD) comprising specific epitopes, including a self B cell epitope of amyloid peptide, a foreign T cell epitope derived from conventional vaccines or pathogens and a molecular adjuvant are disclosed. The approach uses a plurality of copies of the B cell epitope in vaccine composition to significantly enhance the anti-amyloid beta humoral responce. Inclusion of various Th epitopes in the composition allows quick and potent induction od potent anti-amyloid beta antibody responses using pre-existing memory CD4+ Th cells induced in a general population by previous infections or immunizations with conventionalvaccines.